Etoposide

Generic Name: Etoposide

Brand Names: Etopophos, Toposar, Vepesid

Drug Type: Small Molecule

Chemical Formula: C_₂₉H_₃₂O_₁₃

CAS Number: 33419-42-0

Unique Ingredient Identifier: 6PLQ3CP4P3

Background: A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle.

Indication: For use in combination with other chemotherapeutic agents in the treatment of refractory testicular tumors and as first line treatment in patients with small cell lung cancer. Also used to treat other malignancies such as lymphoma, non-lymphocytic leukemia, and glioblastoma multiforme.

Associated Conditions: Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Advanced Hodgkin's Lymphoma, Ewing's Sarcoma, Gestational Trophoblastic Neoplasia, Merkel cell cancer, Multiple Myeloma (MM), Neuroblastoma (NB), Neuroendocrine Tumors, Non-Hodgkin's Lymphomas, Non-Small Cell Lung Cancer (NSCLC), Osteosarcoma, Ovarian Cancer, Prostate Cancer, Retinoblastoma, Small Cell Lung Cancer (SCLC), Wilms' tumor, Locally advanced Thymoma, Metastatic Thymic Cancer, Refractory Sarcoma, Refractory Testicular cancer

Associated Therapies: -

Clinical Trials

G-CSF and Pegfilgrastim in Treating Neutropenia in Patients Undergoing Radiation Therapy and Chemotherapy for Limited Stage Small Cell Lung Cancer

Phase 2

Completed

Conditions: Lung Cancer

Interventions: Drug: Filgrastim
Drug: Pegfilgrastim
Drug: Etoposide
Drug: Cisplatin
Radiation: radiation therapy

First Posted Date: 2007-11-07

Last Posted Date: 2019-05-29

Lead Sponsor: Radiation Therapy Oncology Group

Target Recruit Count: 5

Registration Number: NCT00554463

Locations: 🇺🇸
McDowell Cancer Center at Akron General Medical Center, Akron, Ohio, United States
🇺🇸
Charles M. Barrett Cancer Center at University Hospital, Cincinnati, Ohio, United States
🇺🇸
Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio, United States

and more 11 locations

Combination Chemotherapy, Autologous Stem Cell Transplant, and/or Radiation Therapy in Treating Young Patients With Extraocular Retinoblastoma

Phase 3

Active, not recruiting

Conditions: Extraocular Retinoblastoma

Interventions: Procedure: Autologous Bone Marrow Transplantation
Procedure: Autologous Hematopoietic Stem Cell Transplantation
Drug: Carboplatin
Drug: Cisplatin
Drug: Cyclophosphamide
Drug: Etoposide
Biological: Filgrastim
Procedure: In Vitro-Treated Peripheral Blood Stem Cell Transplantation
Radiation: Radiation Therapy
Drug: Thiotepa
Drug: Vincristine Sulfate

First Posted Date: 2007-11-07

Last Posted Date: 2024-10-22

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 60

Registration Number: NCT00554788

Locations: 🇺🇸
Children's Healthcare of Atlanta - Arthur M Blank Hospital, Atlanta, Georgia, United States
🇺🇸
Children's Hospital of Alabama, Birmingham, Alabama, United States
🇺🇸
University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States

and more 70 locations

Etoposide and Celecoxib in Patients With Advanced Cancer

Phase 1

Completed

Conditions: Unspecified Adult Solid Tumor, Protocol Specific

First Posted Date: 2007-10-30

Last Posted Date: 2012-11-22

Lead Sponsor: City of Hope Medical Center

Target Recruit Count: 58

Registration Number: NCT00551005

Different Therapies in Treating Infants With Newly Diagnosed Acute Leukemia

Not Applicable

Conditions: Leukemia

First Posted Date: 2007-10-30

Last Posted Date: 2019-07-30

Lead Sponsor: Dutch Childhood Oncology Group

Target Recruit Count: 445

Registration Number: NCT00550992

Locations: 🇨🇿
University Hospital Motol, Prague, Czechia
🇫🇷
CHR Hotel Dieu, Nantes, France
🇺🇸
Children's Hospital and Regional Medical Center - Seattle, Seattle, Washington, United States

and more 10 locations

Donor Peripheral Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other Disorders

Phase 2

Active, not recruiting

Conditions: Myelodysplastic Syndromes
Myelodysplastic/Myeloproliferative Diseases
Precancerous/Nonmalignant Condition
Chronic Myeloproliferative Disorders
Graft Versus Host Disease
Leukemia
Lymphoma
Multiple Myeloma and Plasma Cell Neoplasm

Interventions: Drug: cyclosporine
Drug: cyclophosphamide
Drug: busulfan
Drug: etoposide
Drug: fludarabine phosphate
Drug: melphalan
Drug: methotrexate
Drug: mycophenolate mofetil
Drug: sirolimus
Drug: tacrolimus
Procedure: allogeneic hematopoietic stem cell transplantation
Procedure: peripheral blood stem cell transplantation
Radiation: total-body irradiation

First Posted Date: 2007-10-16

Last Posted Date: 2024-04-02

Lead Sponsor: City of Hope Medical Center

Target Recruit Count: 260

Registration Number: NCT00544115

High-Dose Chemotherapy in Treating Patients Undergoing Stem Cell Transplant for Recurrent or Refractory Hodgkin's Lymphoma

Not Applicable

Completed

Conditions: Lymphoma

First Posted Date: 2007-10-16

Last Posted Date: 2010-02-09

Lead Sponsor: City of Hope Medical Center

Target Recruit Count: 30

Registration Number: NCT00544570

R-(-)-Gossypol Acetic Acid, Cisplatin, and Etoposide in Treating Patients With Advanced Solid Tumors or Extensive Stage Small Cell Lung Cancer

Phase 1

Completed

Conditions: Extensive Stage Small Cell Lung Cancer
Unspecified Adult Solid Tumor, Protocol Specific

Interventions: Drug: R-(-)-gossypol acetic acid
Drug: cisplatin
Drug: etoposide

First Posted Date: 2007-10-16

Last Posted Date: 2014-04-02

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 27

Registration Number: NCT00544596

Locations: 🇺🇸
UW Health Oncology - 1 South Park, Madison, Wisconsin, United States
🇺🇸
University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States
🇺🇸
Sanford Cancer Center-Oncology Clinic, Sioux Falls, South Dakota, United States

and more 1 locations

Busulfan, Etoposide, and Intensity-Modulated Radiation Therapy Followed By Donor Stem Cell Transplant in Treating Patients With Advanced Myeloid Cancer

Phase 1

Terminated

Conditions: Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)
Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)
Recurrent Adult Acute Myeloid Leukemia
Adult Acute Myeloid Leukemia in Remission
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)
Blastic Phase Chronic Myelogenous Leukemia
Childhood Acute Myeloid Leukemia in Remission
Previously Treated Myelodysplastic Syndromes

Interventions: Drug: busulfan
Drug: etoposide
Radiation: intensity-modulated radiation therapy
Procedure: allogeneic hematopoietic stem cell transplantation
Procedure: allogeneic bone marrow transplantation
Procedure: peripheral blood stem cell transplantation
Radiation: tomotherapy

First Posted Date: 2007-10-08

Last Posted Date: 2023-11-30

Lead Sponsor: City of Hope Medical Center

Target Recruit Count: 25

Registration Number: NCT00540995

Locations: 🇺🇸
City of Hope, Duarte, California, United States

Autologous Stem Cell Rescue With CD133+ Selected Cells in High-Risk Neuroblastoma

Phase 2

Terminated

Conditions: Neuroblastoma

Interventions: Drug: Carboplatin
Drug: Etoposide
Drug: Melphalan
Procedure: Stem Cell Infusion
Device: ClinicMACS

First Posted Date: 2007-10-04

Last Posted Date: 2019-07-26

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 3

Registration Number: NCT00539500

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

A Phase I/II Study to Determine the Maximum Tolerated Dose (MTD) and Safety of CC-4047 (Pomalidomide) Administered in Conjunction With Cisplatin and Etoposide

Phase 1

Terminated

Conditions: Carcinoma, Small Cell

Interventions: Drug: Pomalidomide
Drug: Cisplatin
Drug: Etoposide

First Posted Date: 2007-10-01

Last Posted Date: 2019-11-19

Lead Sponsor: Celgene

Target Recruit Count: 22

Registration Number: NCT00537511

Locations: 🇺🇸
Pennsylvania State University, Hershey, Pennsylvania, United States
🇺🇸
Ireland Cancer Center, Case Western Reserve University, Division of Hematology/Oncology, Cleveland, Ohio, United States
🇺🇸
University of Texas Southwestern Medical Center, Dallas, Texas, United States

and more 3 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy